Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson's disease

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Hracská, Zsuzsanna ^a   Baranyi, Mária ^a   Csölle, Cecilia ^a   Gölöncsér, Flóra ^a   Madarsz, Emilia ^a   Kittel, Ágnes ^a   Sperlágh, Beta ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 ARACHIDONOYLGLYCEROL; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOSINE TRIPHOSPHATE; AMINO ACID; DOPAMINE; ENDOCANNABINOID; MESSENGER RNA; NORADRENALIN; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X7 RECEPTOR; ROTENONE; TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL STRAIN; CONTROLLED STUDY; CORPUS STRIATUM; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; IN VITRO STUDY; IN VIVO STUDY; MESENCEPHALON; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; SUBSTANTIA NIGRA; SURVIVAL; TISSUE CULTURE; UPREGULATION; WILD TYPE;

ANIMALIA; MUS;

EID: 79955512752     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-28     Document Type: Article

References (63)

1. Involvement of P2 receptors in the growth and survival of neurons in the CNS. H Franke P Illes, Pharmacol Ther 2006 109 297 324 10.1016/j.pharmthera. 2005.06.002 16102837 (Pubitemid 43132815)
2. The P2X7 purinergic receptor: from physiology to neurological disorders. SD Skaper P Debetto P Giusti, FASEB J 2010 24 337 345 10.1096/fj.09-138883 19812374
3. P2X7 receptors in the nervous system. B Sperlagh ES Vizi K Wirkner P Illes, Prog Neurobiol 2006 78 327 346 10.1016/j.pneurobio.2006.03.007 16697102
4. Signaling at purinergic P2X receptors. A Surprenant RA North, Annu Rev Physiol 2009 71 333 359 10.1146/annurev.physiol.70.113006.100630 18851707
5. Pharmacology of cloned P2X receptors. RA North A Surprenant, Annu Rev Pharmacol Toxicol 2000 40 563 580 10.1146/annurev.pharmtox.40.1.563 10836147 (Pubitemid 30340693)
6. A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. A Nicke YH Kuan M Masin J Rettinger B Marquez-Klaka O Bender DC Gorecki RD Murrell-Lagnado F Soto, J Biol Chem 2009 284 25813 25822 10.1074/jbc.M109.033134 19546214
7. Emerging challenges of assigning P2X7 receptor function and immunoreactivity in neurons. CM Anderson M Nedergaard, Trends in neurosciences 2006 29 257 262 10.1016/j.tins.2006.03.003 16564580
8. Functional evidence for presynaptic P2X7 receptors in adult rat cerebrocortical nerve terminals. S Alloisio C Cervetto M Passalacqua R Barbieri G Maura M Nobile M Marcoli, FEBS Lett 2008 582 3948 3953 10.1016/j.febslet.2008. 10.041 18977353
9. Lack of ATP-evoked GABA and glutamate release in the hippocampus of P2X7 receptor-/- mice. L Papp ES Vizi B Sperlagh, Neuroreport 2004 15 2387 2391 10.1097/00001756-200410250-00017 15640761 (Pubitemid 39488925)
10. Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. B Sperlagh A Kofalvi J Deuchars L Atkinson CJ Milligan NJ Buckley ES Vizi, J Neurochem 2002 81 1196 1211 10.1046/j.1471-4159. 2002.00920.x 12068068 (Pubitemid 34809254)
11. A role for P2X7 in microglial proliferation. F Bianco S Ceruti A Colombo M Fumagalli D Ferrari C Pizzirani M Matteoli F Di Virgilio MP Abbracchio C Verderio, J Neurochem 2006 99 745 758 10.1111/j.1471-4159.2006.04101.x 16836656
12. The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore. M Monif CA Reid KL Powell ML Smart DA Williams, J Neurosci 2009 29 3781 3791 10.1523/JNEUROSCI.5512-08.2009 19321774
13. P2X(7) receptors on microglial cells mediate injury to cortical neurons in vitro. SD Skaper L Facci AA Culbert NA Evans I Chessell JB Davis JC Richardson, Glia 2006 54 234 242 10.1002/glia.20379 16817206 (Pubitemid 44230860)
14. The P2X7 receptor: a key player in IL-1 processing and release. D Ferrari C Pizzirani E Adinolfi RM Lemoli A Curti M Idzko E Panther F Di Virgilio, J Immunol 2006 176 3877 3883 16547218 (Pubitemid 44264361)
15. P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. A Witting L Walter J Wacker T Moller N Stella, Proc Natl Acad Sci USA 2004 101 3214 3219 10.1073/pnas.0306707101 14976257 (Pubitemid 38327760)
16. ATP induces a rapid and pronounced increase in 2-arachidonoylglycerol production by astrocytes, a response limited by monoacylglycerol lipase. L Walter T Dinh N Stella, J Neurosci 2004 24 8068 8074 10.1523/JNEUROSCI.2419-04. 2004 15371507 (Pubitemid 39280826)
17. Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. W Peng ML Cotrina X Han H Yu L Bekar L Blum T Takano GF Tian SA Goldman M Nedergaard, Proc Natl Acad Sci USA 2009 106 12489 12493 10.1073/pnas.0902531106 19666625
18. P2X7 receptor inhibition improves recovery after spinal cord injury. X Wang G Arcuino T Takano J Lin WG Peng P Wan P Li Q Xu QS Liu SA Goldman M Nedergaard, Nat Med 2004 10 821 827 10.1038/nm1082 15258577 (Pubitemid 39070855)
19. Block of purinergic P2X(7) receptor is neuroprotective in an animal model of Alzheimer's disease. JK Ryu JG McLarnon, Neuroreport 2008 19 1715 1719 10.1097/WNR.0b013e3283179333 18852683
20. Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. M Diaz-Hernandez M Diez-Zaera J Sanchez-Nogueiro R Gomez-Villafuertes JM Canals J Alberch MT Miras-Portugal JJ Lucas, FASEB J 2009 23 1893 1906 10.1096/fj.08-122275 19171786
21. Neuroprotective effects of the P2 receptor antagonist PPADS on focal cerebral ischaemia-induced injury in rats. A Lammer A Gunther A Beck U Krugel H Kittner D Schneider P Illes H Franke, Eur J Neurosci 2006 23 2824 2828 10.1111/j.1460-9568.2006.04825.x 16817887 (Pubitemid 43801476)
22. P2X7 receptor modulation on microglial cells and reduction of brain infarct caused by middle cerebral artery occlusion in rat. A Melani S Amadio M Gianfriddo MG Vannucchi C Volonte G Bernardi F Pedata G Sancesario, J Cereb Blood Flow Metab 2006 26 974 982 10.1038/sj.jcbfm.9600250 16395292 (Pubitemid 43980413)
23. Extracellular ATP and P2X7 receptors in neurodegeneration. R Le Feuvre D Brough N Rothwell, Eur J Pharmacol 2002 447 261 269 10.1016/S0014-2999(02)01848- 4 12151017 (Pubitemid 34874459)
24. Role of P2X7 receptors in ischemic and excitotoxic brain injury in vivo. RA Le Feuvre D Brough O Touzani NJ Rothwell, J Cereb Blood Flow Metab 2003 23 381 384 12621313 (Pubitemid 36307582)
25. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. C Matute I Torre F Perez-Cerda A Perez-Samartin E Alberdi E Etxebarria AM Arranz R Ravid A Rodriguez-Antiguedad M Sanchez-Gomez M Domercq, J Neurosci 2007 27 9525 9533 10.1523/JNEUROSCI.0579-07.2007 17728465 (Pubitemid 47358223)
26. Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic activity in lymphocytes. L Chen CF Brosnan, J Immunol 2006 176 3115 3126 16493071
27. Experimental autoimmune encephalomyelitis disrupts endocannabinoid- mediated neuroprotection. A Witting L Chen E Cudaback A Straiker L Walter B Rickman T Moller C Brosnan N Stella, Proc Natl Acad Sci USA 2006 103 6362 6367 10.1073/pnas.0510418103 16571660
28. P2 receptor expression in the dopaminergic system of the rat brain during development. C Heine A Wegner J Grosche C Allgaier P Illes H Franke, Neuroscience 2007 149 165 181 10.1016/j.neuroscience.2007.07.015 17869006 (Pubitemid 47488653)
29. Mapping P2X and P2Y receptor proteins in striatum and substantia nigra: An immunohistological study. S Amadio C Montilli B Picconi P Calabresi C Volonte, Purinergic Signal 2007 3 389 398 10.1007/s11302-007-9069-8 18404452
30. P2X7 receptors in rat brain: presence in synaptic terminals and granule cells. MT Miras-Portugal M Diaz-Hernandez L Giraldez C Hervas R Gomez-Villafuertes RP Sen J Gualix J Pintor, Neurochem Res 2003 28 1597 1605 10.1023/A:1025690913206 14570406 (Pubitemid 37193543)
31. Microglia response and P2 receptor participation in oxygen/glucose deprivation-induced cortical damage. F Cavaliere K Dinkel K Reymann, Neuroscience 2005 136 615 623 10.1016/j.neuroscience.2005.04.038 16344139 (Pubitemid 41774713)
32. Extracellular ATP mediates necrotic cell swelling in SN4741 dopaminergic neurons through P2X7 receptors. DJ Jun J Kim SY Jung R Song JH Noh YS Park SH Ryu JH Kim YY Kong JM Chung KT Kim, J Biol Chem 2007 282 37350 37358 10.1074/jbc.M707915200 17962183
33. 3H]dopamine efflux after in vitro rotenone exposure in rat striatal slices. E Milusheva M Baranyi E Kormos Z Hracsko E Sylvester Vizi B Sperlagh, Neuropharmacology 2010 58 816 825 10.1016/j.neuropharm.2009.11.017 19995567
34. D-beta-hydroxybutyrate prevents MPP+-induced neurotoxicity in PC12 cells. B Cheng X Yang C Chen D Cheng X Xu X Zhang, Neurochem Res 2010 35 444 451 10.1007/s11064-009-0078-6 19851865
35. Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism. Y Sai Q Wu W Le F Ye Y Li Z Dong, Toxicol In Vitro 2008 22 1461 1468 10.1016/j.tiv.2008.04.019 18579341
36. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine has a transient proliferative effect on PC12h cells and nerve growth factor additively promotes this effect: possible involvement of distinct mechanisms of activation of MAP kinase family proteins. K Shimoke M Kudo, Brain Res Dev Brain Res 2002 133 105 114 11882341 (Pubitemid 34211996)
37. Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors. LH Jiang AB Mackenzie RA North A Surprenant, Mol Pharmacol 2000 58 82 88 10860929 (Pubitemid 30452530)
38. Negative and positive allosteric modulators of the P2X(7) receptor. AD Michel LJ Chambers DS Walter, Br J Pharmacol 2008 153 737 750 10.1038/sj.bjp.0707625 18071294 (Pubitemid 351271766)
39. P2 receptor modulation and cytotoxic function in cultured CNS neurons. S Amadio N D'Ambrosi F Cavaliere B Murra G Sancesario G Bernardi G Burnstock C Volonte, Neuropharmacology 2002 42 489 501 10.1016/S0028-3908(01)00197-6 11955520 (Pubitemid 34304242)
40. Chromatographic analysis of dopamine metabolism in a Parkinsonian model. M Baranyi E Milusheva ES Vizi B Sperlagh, J Chromatogr A 2006 1120 13 20 10.1016/j.chroma.2006.03.018 16580006 (Pubitemid 43866771)
41. Increased sensitivity of striatal dopamine release to H2O2 upon chronic rotenone treatment. E Milusheva M Baranyi A Kittel B Sperlagh ES Vizi, Free Radic Biol Med 2005 39 133 142 10.1016/j.freeradbiomed.2005.02.034 15925285 (Pubitemid 40733123)
42. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. TB Sherer JH Kim R Betarbet JT Greenamyre, Exp Neurol 2003 179 9 16 10.1006/exnr.2002.8072 12504863 (Pubitemid 36062614)
43. Purinergic modulation of microglial cell activation. B Sperlagh P Illes, Purinergic Signal 2007 3 117 127 10.1007/s11302-006-9043-x 18404425
44. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. T Takenouchi K Sekiyama A Sekigawa M Fujita M Waragai S Sugama Y Iwamaru H Kitani M Hashimoto, Arch Immunol Ther Exp (Warsz) 2010 58 91 96 10.1007/s00005-010-0069-y
45. Interaction and interrelation of P2X7 and P2X4 receptor complexes in mouse lung epithelial cells. K Weinhold U Krause-Buchholz G Rodel M Kasper K Barth, Cell Mol Life Sci 2010 67 2631 2642 10.1007/s00018-010-0355-1 20405163
46. Identification and characterization of splice variants of the human P2X7 ATP channel. B Cheewatrakoolpong H Gilchrest JC Anthes S Greenfeder, Biochem Biophys Res Commun 2005 332 17 27 10.1016/j.bbrc.2005.04.087 15896293 (Pubitemid 40719451)
47. A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. YH Feng X Li L Wang L Zhou GI Gorodeski, J Biol Chem 2006 281 17228 17237 10.1074/jbc.M602999200 16624800
48. Activation of P2X(7) receptors stimulates the expression of P2Y(2) receptor mRNA in astrocytes cultured from rat brain. I D'Alimonte R Ciccarelli P Di Iorio E Nargi S Buccella P Giuliani MP Rathbone S Jiang F Caciagli P Ballerini, Int J Immunopathol Pharmacol 2007 20 301 316 17624242 (Pubitemid 47104850)
49. P2Y receptors activate neuroprotective mechanisms in astrocytic cells. NE Chorna LI Santiago-Perez L Erb CI Seye JT Neary GY Sun GA Weisman FA Gonzalez, J Neurochem 2004 91 119 132 10.1111/j.1471-4159.2004.02699.x 15379893 (Pubitemid 39314943)
50. P2X7 nucleotide receptor is coupled to GSK-3 inhibition and neuroprotection in cerebellar granule neurons. F Ortega R Perez-Sen EG Delicado MT Miras-Portugal, Neurotox Res 2009 15 193 204 10.1007/s12640-009-9020-6 19384592
51. P2X7, NMDA and BDNF receptors converge on GSK3 phosphorylation and cooperate to promote survival in cerebellar granule neurons. F Ortega R Perez-Sen V Morente EG Delicado MT Miras-Portugal, Cell Mol Life Sci 2010 67 1723 1733 10.1007/s00018-010-0278-x 20146080
52. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. A Klegeris CJ Bissonnette PL McGeer, Br J Pharmacol 2003 139 775 786 10.1038/sj.bjp.0705304 12813001 (Pubitemid 36819605)
53. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. G Marsicano S Goodenough K Monory H Hermann M Eder A Cannich SC Azad MG Cascio SO Gutierrez M van der Stelt,, et al. Science 2003 302 84 88 10.1126/science. 1088208 14526074 (Pubitemid 37210691)
54. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. D Panikashvili C Simeonidou S Ben-Shabat L Hanus A Breuer R Mechoulam E Shohami, Nature 2001 413 527 531 10.1038/35097089 11586361 (Pubitemid 32938751)
55. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. M Garcia-Arencibia S Gonzalez E de Lago JA Ramos R Mechoulam J Fernandez-Ruiz, Brain Res 2007 1134 162 170 17196181 (Pubitemid 46135535)
56. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. I Lastres-Becker F Molina-Holgado JA Ramos R Mechoulam J Fernandez-Ruiz, Neurobiol Dis 2005 19 96 107 10.1016/j.nbd.2004.11.009 15837565 (Pubitemid 40544727)
57. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. S Jimenez D Baglietto-Vargas C Caballero I Moreno-Gonzalez M Torres R Sanchez-Varo D Ruano M Vizuete A Gutierrez J Vitorica, J Neurosci 2008 28 11650 11661 10.1523/JNEUROSCI.3024-08.2008 18987201
58. Altered cytokine production in mice lacking P2X(7) receptors. M Solle J Labasi DG Perregaux E Stam N Petrushova BH Koller RJ Griffiths CA Gabel, J Biol Chem 2001 276 125 132 11016935 (Pubitemid 32050297)
59. P2X receptor activation elicits transporter-mediated noradrenaline release from rat hippocampal slices. L Papp T Balazsa A Kofalvi F Erdelyi G Szabo ES Vizi B Sperlagh, J Pharmacol Exp Ther 2004 310 973 980 10.1124/jpet.104.066712 15084650 (Pubitemid 39108917)
60. Purinergic receptor modulation of BV-2 microglial cell activity: potential involvement of p38 MAP kinase and CREB. VM Brautigam C Frasier M Nikodemova JJ Watters, J Neuroimmunol 2005 166 113 125 10.1016/j.jneuroim.2005. 05.012 15979729 (Pubitemid 41078772)
61. A new mathematical model for relative quantification in real-time RT-PCR. MW Pfaffl, Nucleic Acids Res 2001 29 45 10.1093/nar/29.9.e45 11328886
62. Protein measurement with the Folin phenol reagent. OH Lowry NJ Rosebrough AL Farr RJ Randall, J Biol Chem 1951 193 265 275 14907713
63. The energy charge of the adenylate pool as a regulatory parameter. Interaction with feedback modifiers. DE Atkinson, Biochemistry 1968 7 4030 4034 10.1021/bi00851a033 4972613